Wearable sensor for opioids detection based on electrochemical sensor arrayintegrated with Bluetooth device

项目摘要/摘要 基于电化学传感器阵列的可穿戴类阿片检测传感器 与蓝牙设备集成 在这个二期工程中，我们将开发一种新型的电化学传感器阵列，它具有 高灵敏度(检测下限为ng/毫升)、增强的药物特异性、长期耐用性、 耗电量低，生产成本低。到第二阶段结束时，20% 将生产设备(以及每个设备42个感应盒)，并准备用于 完成第二阶段的商业化(TRL 9)。提供超高的 为了提高电极的灵敏度，将采用纳米多孔硅作为工作电极的衬底。 此外，该方法的进步包括高度整合所有 一个微芯片上的功能模块，与用户界面进行无线通信 (智能手机、电脑)，成本低，维护通过长期耐用，低 耗电量大，生产成本低。 第二阶段的具体目标如下： ·开发感官可穿戴设备的原型，其中包括 电化学传感器阵列调谐到六个靶标阿片和六个非阿片 麻醉药品 ·证明该样机能够以超高分辨率检测毒品 灵敏度(在ng/L范围内)和高选择性/低交叉反应 ·到第二阶段结束时，生产20台准备商业化的设备(TRL 9) 在第二阶段，可穿戴设备的原型将进一步优化和 发展到商业就绪的水平。第二阶段的主要目标包括 单个传感器的最低检测和两个传感器的制造 六种阿片类药物和六种非阿片类麻醉剂的可互换感应盒； 将传感模块与印刷电路板集成以进行数据调节， 处理和无线传输；人体受试者的两级试验；提交 FDA申请；制造20个设备和墨盒，准备用于 商业化(TRL 9)；专利申请；与最终用户建立联系， 采购商和风险集团，以便产品商业化可以在 第二阶段(我们将把公司利润用于销售和营销)。

Project Summary/Abstract Wearable sensor for opioids detection based on electrochemical sensor array integrated with Bluetooth device In this Phase II project, we will develop a new electrochemical sensor array with ultra- high sensitivity (ng/mL limit of detection), enhanced drug specificity, long-term durability, low power consumption, and cost-effective production. By the end of Phase II, 20 devices (along with 42 sensory cartridges for each) will be produced and ready for commercialization (TRL 9) upon completion of Phase II. To provide an ultra-high sensitivity, nanoporous silicon will be employed as a substrate for the working electrode. Additionally, advancements of the approach include a high level of integration of all functional modules on one microchip, wireless communication with user interface (smartphone, computer), low cost and maintenance through long-term durability, low power consumption, and cost-effective production. The specific aims of Phase II are as follows: • Develop a prototype of the sensory wearable device, which comprises an electrochemical sensor array tuned to six target opioids and six non-opioid narcotics • Demonstrate that the prototype is capable of narcotic detection with ultra-high sensitivity (within ng/L range) and high selectivity/low cross-reactivity • By the end of Phase II, produce 20 devices (TRL 9) ready for commercialization In Phase II, the prototype of the wearable device will be further optimized and developed to the level of commercial readiness. Major objectives of Phase II include optimization of individual sensors to the lowest limit of detection and fabrication of two interchangeable sensory cartridges for six opioids and six non-opioid narcotics; integration of the sensory module with the printed circuit board for data conditioning, processing, and wireless transmittance; two-level trials with human subjects; submission of an FDA application; fabrication of 20 devices and cartridges ready for commercialization (TRL 9); patent filing; and establishing contacts with end-users, purchasers and venture groups so that product commercialization can be started after Phase II (we will use the company profit for sales and marketing).